Veradermics, Inc
MANENYSE
$111.32
↑ +5.2%Jul 17 close · end-of-day
Price
1Y↑ +194.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$82.9M
Enterprise Value
-$307.9M
P/E
—
P/S
—
P/B
0.2
EV/EBITDA
—
PEG
—
FCF Yield
-86.4%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$70.0M
Free Cash Flow (TTM)
-$71.6M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-17.9%
ROIC
—
Debt / Equity
—
Net Cash
$390.8M
Return 1Y
—
Company profile
We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our principal executive offices are located in New Haven, Connecticut.
- CEO
- Reid Waldman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 19
- Headquarters
- Connecticut
- Website
- www.veradermics.com
Management & directors
- Durso Timothy AugustChief Technical Officer
- Waldman Reid AlexanderChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
MANE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.32↓ -93.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$26.8M | -$72.3M |
| Net income | -$26.5M | -$70.0M |
| Diluted EPS | -$37.05 | -$111.91 |
| Operating cash flow | -$23.7M | -$71.6M |
| Free cash flow | -$23.7M | -$71.6M |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
| Line item | Q1 '25 | Q1 '26 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$12.9M | -$29.9M |
| Net income | -$12.4M | -$27.2M |
| Diluted EPS | -$19.79 | -$1.32 |
| Operating cash flow | -$13.3M | -$21.2M |
| Free cash flow | -$13.3M | -$21.2M |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
Company news
Jul 19, 2026
Jul 15, 2026
- 5d agoSector Update: Healthcare Stocks Advance Late Afternoonfinance.yahoo.com
- 5d agoVeradermics Hair Loss Pill Shows Strong Phase II Signal in Womenmarketbeat.com
- 5d agoVeradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readoutfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-02-06 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 19,338 | $36.55 | $706,803.90 | filing |
| 2026-02-06 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 11,183 | $35.97 | $402,252.51 | filing |
| 2026-02-05 | Longitude Capital Partners V, LLC | Buy | 882,353 | $17.00 | $15.0M | filing |
| 2026-02-05 | ENRIGHT PATRICK G | Buy | 882,353 | $17.00 | $15.0M | filing |
| 2026-02-05 | CHILDS JOHN W | Buy | 294,117 | $17.00 | $5.0M | filing |
| 2026-02-05 | CHILDS JOHN W | Buy | 294,117 | $17.00 | $5.0M | filing |
| 2026-02-05 | Longitude Capital Partners V, LLC | Buy | 192,647 | $17.00 | $3.3M | filing |
| 2026-02-05 | ENRIGHT PATRICK G | Buy | 192,647 | $17.00 | $3.3M | filing |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 38,771 | $37.63 | $1.5M | filing |
| 2026-02-05 | Coric Vlad | Buy | 58,823 | $17.00 | $999,991.00 | filing |
| 2026-02-05 | Coric Vlad | Buy | 58,823 | $17.00 | $999,991.00 | filing |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 19,199 | $36.93 | $709,019.07 | filing |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 17,835 | $38.67 | $689,679.45 | filing |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 16,563 | $39.80 | $659,207.40 | filing |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 3,832 | $36.07 | $138,220.24 | filing |
| 2026-02-05 | Coric Vlad | C | 117,112 | — | — | filing |
| 2026-02-05 | Waldman Reid Alexander· Chief Executive Officer | C | 1,437 | — | — | filing |
| 2026-02-05 | Coric Vlad | C | 33,706 | — | — | filing |
| 2026-02-05 | CHILDS JOHN W | C | 480,269 | — | — | filing |
| 2026-02-05 | CHILDS JOHN W | C | 906,862 | — | — | filing |
| 2026-02-05 | CHILDS JOHN W | C | 520,758 | — | — | filing |
| 2026-02-05 | Grant-Kels Jane M. | C | 2,455 | — | — | filing |
| 2026-02-05 | Longitude Capital Partners V, LLC | C | 1,236,631 | — | — | filing |
| 2026-02-05 | Longitude Capital Partners V, LLC | C | 1,171,121 | — | — | filing |
| 2026-02-05 | Longitude Capital Partners V, LLC | C | 1,171,121 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.